CLEAN
Clean Science and Technology share price & financials
- Price
- ₹744.4
- Market cap
- ₹8.5k Cr
- Sector
- Chemicals
- Calls analysed
- 8
Clean Science and Technology Limited Q1 FY27
What went well
- Consolidated sales reached highest ever at INR 264 crores, growing 7% QoQ and 10% YoY.
- Standalone EBITDA margin at 43% and PAT margin at 36%, reflecting strong profitability.
- HALS business scaled up to 22% of sales, contributing to operating leverage and profit improvement.
What to watch
- Geopolitical headwinds impacted raw material supply chain and costs, and non-availability of shipping vessels affected timely exports.
- Lost 'a couple of weeks' of production in Q1 due to supply chain and gas issues.
What Clean Science and Technology Limited does
Clean Science and Technology is a Pune-headquartered fine and specialty chemicals manufacturer that develops proprietary, in-house catalytic manufacturing processes rather than licensing third-party technology. It makes chemical intermediates across three reported segments — Performance Chemicals, Pharma & Agro Intermediates, and FMCG Chemicals — that feed into acrylics/superabsorbent polymers, food and feed preservation, sunscreen and cosmetic actives, and pharmaceutical and agrochemical manufacturing. It holds the largest global manufacturing capacity for several flagship products, including MEHQ, BHA, AP and TBHQ. Manufacturing is concentrated at Kurkumbh Industrial Area, Maharashtra, across three company units plus a fourth HALS-dedicated facility housed in wholly owned subsidiary Clean Fino Chem Ltd.
Segments
- Performance Chemicals
- Pharma & Agro Intermediates
- FMCG Chemicals
- Manufacturing units
- 4 units at Kurkumbh Industrial Area, Maharashtra — Unit 1 (7 plants), Unit 2 (4 plants), Unit 3 (5 plants), plus a dedicated HALS facility (Unit 4) under subsidiary Clean Fino Chem Ltd.
- Global market position
- Ranked No.1 or No.2 worldwide in MEHQ, BHA, AP, TBHQ, HALS 701, 4-MAP, Anisole and DHDT
- Customer base
- 500+ global and domestic customers across 35+ countries
- Product portfolio
- 11+ named specialty chemicals across 3 operating segments
- R&D infrastructure
- 4 R&D facilities with a pilot plant and application lab; 90+ scientists including 9 PhDs
- Workforce
- 1,500+ employees (~10% women staff)
Guidance record · Q1 FY27
what the last two calls moved 25 tracked 5 delivered 6 missed 14 open- HALS Volume delivered said Q2 FY25 Promised: 2,000 tons in Calendar Year 2025 Q1 FY27: No new update. Promise remains achieved.
- Pharma Intermediate (DHDT) Commercialization missed said Q2 FY25 Promised: Q3 FY25 Q1 FY27: No new update. Promise remains missed as the plant was repurposed.
- Performance Chemical 2 Commercialization delayed said Q1 FY26 Promised: Q4 FY26 Q1 FY27: Commercialization further delayed to Q3 FY27 (Nov-Dec '26), a slip from the previous guidance of Sep '26 (Q2 FY27).
All 25 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue down 5.9%, net profit down 5.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 228 | 232 | 245 | 220 | 213 −7% | 185 −20% | 197 −20% | 207 −6% |
| EBITDA | 95 | 102 | 105 | 101 | 92 −3% | 72 −29% | 88 −16% | 87 −14% |
| Net profit | 67 | 74 | 79 | 77 | 65 −3% | 52 −30% | 58 −27% | 73 −5% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −27.2% 1Y
1Y: ₹1,156.6 on 10 Sept 2025 → ₹842.05. High ₹1,195.7 (17 Sept 2025), low ₹656.4 (30 Mar 2026).
How the price took the results
close before → close after
- Q1 FY27
- +4.1%
- 1 Aug
- Q4 FY26
- +0.1%
- 14 May
- Q3 FY26
- −6.1%
- 31 Jan
- Q2 FY26
- −0.3%
- 6 Nov
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue fell 4.5% a year over 3 years, FY23 to FY26. Operating margin held at 43.3%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹936 Cr | ₹789 Cr | ₹922 Cr | ₹815 Cr |
| Operating profit | ₹402 Cr | ₹338 Cr | ₹400 Cr | ₹353 Cr |
| Operating margin | 42.9% | 42.8% | 43.4% | 43.3% |
| Interest | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹36 Cr | ₹44 Cr | ₹44 Cr | ₹44 Cr |
| Net profit | ₹303 Cr | ₹248 Cr | ₹292 Cr | ₹252 Cr |
| Net margin | 32.4% | 31.4% | 31.7% | 30.9% |
| Cash from operations | ₹299 Cr | ₹277 Cr | ₹279 Cr | ₹310 Cr |
| Free cash flow | ₹164 Cr | ₹264 Cr | ₹270 Cr | ₹289 Cr |
| ROCE | 45.0% | 29.0% | 29.0% | 22.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr |
| Reserves | ₹529 Cr | ₹758 Cr | ₹1.0k Cr | ₹1.2k Cr | ₹1.5k Cr | ₹1.6k Cr |
| Borrowings | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Other liabilities | ₹120 Cr | ₹156 Cr | ₹139 Cr | ₹154 Cr | ₹156 Cr | ₹137 Cr |
| Total liabilities | ₹660 Cr | ₹925 Cr | ₹1.2k Cr | ₹1.4k Cr | ₹1.7k Cr | ₹1.8k Cr |
| Fixed assets | ₹186 Cr | ₹296 Cr | ₹427 Cr | ₹401 Cr | ₹351 Cr | ₹340 Cr |
| Capital work in progress | ₹55 Cr | ₹44 Cr | ₹4 Cr | ₹2 Cr | ₹5 Cr | ₹4 Cr |
| Investments | ₹233 Cr | ₹247 Cr | ₹428 Cr | ₹666 Cr | ₹1.1k Cr | ₹1.2k Cr |
| Other assets | ₹187 Cr | ₹338 Cr | ₹300 Cr | ₹302 Cr | ₹281 Cr | ₹285 Cr |
| Total assets | ₹660 Cr | ₹925 Cr | ₹1.2k Cr | ₹1.4k Cr | ₹1.7k Cr | ₹1.8k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, promoters trimmed −23.67 pp while DIIs added +10.31 pp. The shareholder count grew 7% to 2,41,947.
- Promoters
- 51.3%
- FIIs
- 13.4%
- DIIs
- 16.2%
- Government
- 0.0%
- Public
- 19.1%
Since Jun 2025
- Promoters −23.67 pp
- DIIs +10.31 pp
- FIIs +7.16 pp
How it drifted, 12 quarters
Over this window promoters fell from 75.0% to 51.3% — −23.7 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 75.0%, FIIs 6.0%, DIIs 5.2%, Public 13.8%.Dec '23: Promoters 75.0%, FIIs 5.9%, DIIs 5.1%, Public 14.0%.Mar '24: Promoters 75.0%, FIIs 5.9%, DIIs 5.0%, Public 14.1%.Jun '24: Promoters 75.0%, FIIs 6.0%, DIIs 4.5%, Public 14.4%.Sep '24: Promoters 75.0%, FIIs 5.8%, DIIs 4.8%, Public 14.4%.Dec '24: Promoters 75.0%, FIIs 6.0%, DIIs 5.5%, Public 13.6%.Mar '25: Promoters 75.0%, FIIs 6.1%, DIIs 5.8%, Public 13.2%.Jun '25: Promoters 75.0%, FIIs 6.2%, DIIs 5.9%, Public 12.9%.Sep '25: Promoters 51.0%, FIIs 11.1%, DIIs 19.0%, Public 18.9%.Dec '25: Promoters 51.0%, FIIs 10.0%, DIIs 19.8%, Government 0.0%, Public 19.3%.Mar '26: Promoters 51.3%, FIIs 13.4%, DIIs 17.1%, Government 0.0%, Public 18.2%.Jun '26: Promoters 51.3%, FIIs 13.4%, DIIs 16.2%, Government 0.0%, Public 19.1%.
Who is on the register
Named in the Jun 2026 filing
Every holder of Clean Science and Technology Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Ashokkumar Ramkishan Sikchi Huf | 9.96% | unchanged |
| Asha Ashok Boob | 9.50% | −0.10 pp |
| Ashok Ramnarayan Boob Huf | 5.51% | unchanged |
| Nilima Krishnakumar Boob | 5.46% | −0.87 pp |
| Siddhartha Ashok Sikchi | 5.41% | unchanged |
| Amansa Holdings Private Limited FPI fund | 4.37% | unchanged |
| Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund Mutual fund | 4.32% | unchanged |
| Anantroop Financial Advisory Services Private Limited | 3.92% | unchanged |
| SBI Small Cap Fund Mutual fund | 3.22% | −0.06 pp |
| Ashok Ramnarayan Boob | 3.11% | −0.34 pp |
| Krishnakumar Ramnarayan B Oob Huf | 3.04% | unchanged |
| Government Pension Fund Global Sovereign | 2.38% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Mutual funds in CLEAN
Filings to Aug 2026
0 new, 4 added, 2 trimmed, 1 sold out — net −20.98 L shares (−26.7%).
- Held by funds
- ₹471 Cr
- 11 schemes
- Biggest holder
- Nippon India Small Cap Fund
- ₹254 Cr · 0.3% of that fund
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| Nippon India Small Cap Fund Nippon India Mutual Fund | ₹254 Cr | held | Apr '25 |
| Nippon India Multi Cap Fund Nippon India Mutual Fund | ₹116 Cr | held | Aug '25 |
| SBI Comma Fund SBI Mutual Fund | ₹32 Cr | held | Aug '25 |
| HDFC Manufacturing Fund HDFC Mutual Fund | ₹29 Cr | held | Aug '25 |
| SBI MNC Fund SBI Mutual Fund | ₹25 Cr | −2.15 L | Aug '25 |
| Nippon India Nifty Smallcap 250 Index Fund Nippon India Mutual Fund | ₹6 Cr | +0.01 L | Sep '23 |
| HDFC Large and Mid Cap Fund HDFC Mutual Fund | ₹3 Cr | held | Dec '22 |
| SBI Nifty Smallcap 250 Index Fund SBI Mutual Fund | ₹3 Cr | +0.00 L | Sep '23 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Aug 2026
4 added, 2 trimmed — net −20.98 L shares (−26.7%)
- Funds are sitting on
- -33%
- vs est. average cost
- Held by funds
- ₹471 Cr
- 11 schemes · ≈ 5.1% of the company
- Biggest holder
- Nippon India Small Cap Fund
- ₹254 Cr · 0.3% of that fund
- Longest holder
- HDFC Large and Mid Cap Fund
- 3y 8m · since Dec '22
Shares held by these funds +3258%
Aug '23 78.71 L shares Jul '26
What the price assumes
Growth trapTo justify its price of ₹842, this stock must grow earnings at 26% every year for 7 years. Our analysis caps realistic growth at ~-6%. At that growth it is worth ₹156 — downside of 81%.
- Growth the price implies
- 25.6% a year
- for 7 years, fading to 4%
- It has actually compounded at
- -6.0% a year
- net profit, FY23–FY26 · EPS -6.1%
- The gap
- 0.3 pp
- -81% downside if it only repeats history
All earnings calls (7)
Read the Q1 FY27 call →Learn to analyse Clean Science and Technology Limited
Guides on how to read this kind of business and the numbers that matter.